Based on prior studies in the context of chronic kidney disease, we hypothesised that co-inhibition of AT1R and CCR2 may result in a decrease in β-arrestin recruitment but also highly affect CCR2–G protein signalling, possibly through allosteric modulation [27]. This evidence concerns the gene CCR2 and chronic kidney disease.